From DCAT Value Chain Insights (VCI)
The European Medicines Agency (EMA) reports that a previously announced investigation by Italian authorities into the supply of stolen medicines (Herceptin (trastuzumab), Remicade (infliximab), and Alimta (pemetrexed ) has identified two additional products, Avastin (bevacizumab) and Mabthera (rituximab) that have been distributed illegally from their territory.
A document is available that lists the batches of Alimta, Avastin, Herceptin, Mabthera, and Remicade concerned by the ongoing investigation into the theft of vials of these medicines in Italy, as announced by the EMA on April 16 and 17, 2014.
See related story, "EMA Provides Update on Herceptin Theft in Italy; Probe Widened to Include Alimta and Remicade"
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription